Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2a,Condition 2b,Condition 3a,Condition 3b,Condition 4,Condition 5,Condition 6 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,18,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.3041,,0.0462,0.1959,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),54621,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,20,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.7016,,0.0778,0.348,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56029,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,20,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.371,g/mg,0.0992,0.4438,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),55825,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,20,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.3195,g/mg,0.088,0.3935,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),57371,controlled sodium content diet (4 %) (for 21 days),,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,18,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.6335,E-7mole,0.042,0.1781,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),55931,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,18,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,1.1408,E-7mole,0.1226,0.52,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),56557,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,17,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-7.5772,,0.0772,0.3184,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55312,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,19,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-7.4685,,0.0548,0.2389,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56142,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,18,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,50.6667,%,2.8469,12.0782,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),54817,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,18,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,39.6667,%,3.7092,15.7368,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),57261,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,18,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-7.2138,,0.0281,0.1191,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),55662,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,18,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-6.9813,,0.044,0.1867,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),56952,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,15,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,42.6,%,4.3445,16.826,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),55057,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,19,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,45.4737,%,4.1092,17.9114,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),55084,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,15,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,35.0667,%,4.2409,16.425,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),55145,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,18,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,46.0556,%,2.6636,11.3006,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),56284,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours), 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,17,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,57.2353,%,2.0101,8.288,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours),57147,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,15,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,66.2,%,3.6622,14.1835,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours),57180,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours), 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,20,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,99.65,%,0.1817,0.8127,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56316,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,18,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,99.7778,%,0.1292,0.5483,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56477,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,18,,CMO:0000726,concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.0544,10E-7mol/l,0.0054,0.0229,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),55747,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,20,,CMO:0000726,concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.0273,10E-7mol/l,0.0056,0.0251,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56241,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,17,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0335,umol/l,0.0056,0.0231,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54711,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,19,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0385,umol/l,0.0044,0.0191,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54943,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,